| Year |
Citation |
Score |
| 2023 |
Chaudhuri D, Lu T, Jacob B, Abraham S, Shankar P, Poss MA, Neamati N, Camarero JA. Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo. Journal of Controlled Release : Official Journal of the Controlled Release Society. 359: 26-32. PMID 37236320 DOI: 10.1016/j.jconrel.2023.05.026 |
0.338 |
|
| 2022 |
Yao J, Yin Y, Han H, Chen S, Zheng Y, Liang B, Wu M, Shu K, Debnath B, Lombard DB, Wang Q, Cheng K, Neamati N, Liu Y. Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors. European Journal of Medicinal Chemistry. 247: 115024. PMID 36543033 DOI: 10.1016/j.ejmech.2022.115024 |
0.365 |
|
| 2022 |
Liu Y, Debnath B, Kumar S, Lombard DB, Neamati N. Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors. European Journal of Medicinal Chemistry. 241: 114623. PMID 35932566 DOI: 10.1016/j.ejmech.2022.114623 |
0.351 |
|
| 2022 |
Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. Journal of Medicinal Chemistry. 65: 343-368. PMID 34982568 DOI: 10.1021/acs.jmedchem.1c01509 |
0.324 |
|
| 2020 |
Huddle BC, Grimley E, Chtcherbinine M, Buchman CD, Takahashi C, Debnath B, McGonigal SC, Mao S, Li S, Felton J, Pan S, Wen B, Sun D, Neamati N, Buckanovich RJ, et al. Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. European Journal of Medicinal Chemistry. 211: 113060. PMID 33341649 DOI: 10.1016/j.ejmech.2020.113060 |
0.302 |
|
| 2020 |
Shergalis A, Xue D, Gharbia FZ, Driks H, Shrestha B, Tanweer A, Cromer K, Ljungman M, Neamati N. Characterization of aminobenzylphenols as protein disulfide isomerase inhibitors in glioblastoma cell lines. Journal of Medicinal Chemistry. PMID 32830969 DOI: 10.1021/Acs.Jmedchem.0C00728 |
0.325 |
|
| 2020 |
Sanna V, Youssef MF, Pala N, Rogolino D, Carcelli M, Singh PK, Sanchez T, Neamati N, Sechi M. Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. Acs Medicinal Chemistry Letters. 11: 857-861. PMID 32435396 DOI: 10.1021/acsmedchemlett.9b00648 |
0.64 |
|
| 2019 |
Hughes MM, Hooftman A, Angiari S, Tummala P, Zaslona Z, Runtsch MC, McGettrick AF, Sutton CE, Diskin C, Rooke M, Takahashi S, Sundararaj S, Casarotto MG, Dahlstrom JE, Palsson-McDermott EM, ... ... Neamati N, et al. Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation. Cell Reports. 29: 151-161.e5. PMID 31577945 DOI: 10.1016/J.Celrep.2019.08.072 |
0.318 |
|
| 2019 |
Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, Bankhead A, Tamura S, Yang S, Wang X, Wang CC, Rehemtulla A, Ljungman M, Neamati N. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics. 9: 2282-2298. PMID 31149044 DOI: 10.7150/Thno.30621 |
0.571 |
|
| 2019 |
Machiraju PK, Yedla P, Gubbala SP, Bohari T, Abdul JKV, Xu S, Patel R, Chittireddy VRR, Boppana K, Jagarlapudi SARP, Neamati N, Syed R, Amanchy R. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. Computational Biology and Chemistry. 80: 374-383. PMID 31103918 DOI: 10.1016/J.Compbiolchem.2019.04.015 |
0.616 |
|
| 2018 |
Hu S, Jin Y, Liu Y, Ljungman M, Neamati N. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. European Journal of Medicinal Chemistry. 158: 884-895. PMID 30253345 DOI: 10.1016/J.Ejmech.2018.09.037 |
0.313 |
|
| 2017 |
Mehanna WE, Lu T, Debnath B, Lasheen DS, Serya RAT, Abouzid KA, Neamati N. Synthesis, ADMET properties, and biological evaluation of benzothiazole compounds targeting CXCR2. Chemmedchem. PMID 28544630 DOI: 10.1002/cmdc.201700229 |
0.315 |
|
| 2017 |
Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 7: 1543-1588. PMID 28529637 DOI: 10.7150/Thno.15625 |
0.763 |
|
| 2016 |
Zhang FH, Debnath B, Xu ZL, Yang LM, Song LR, Zheng YT, Neamati N, Long YQ. Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction. European Journal of Medicinal Chemistry. 125: 1051-1063. PMID 27810592 DOI: 10.1016/j.ejmech.2016.10.045 |
0.449 |
|
| 2016 |
Ramkumar K, Samanta S, Kyani A, Yang S, Tamura S, Ziemke E, Stuckey JA, Li S, Chinnaswamy K, Otake H, Debnath B, Yarovenko V, Sebolt-Leopold JS, Ljungman M, Neamati N. Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. Nature Communications. 7: 13084. PMID 27703239 DOI: 10.1038/Ncomms13084 |
0.46 |
|
| 2016 |
Sanna V, Nurra S, Pala N, Marceddu S, Pathania D, Neamati N, Sechi M. Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. Journal of Medicinal Chemistry. PMID 27139920 DOI: 10.1021/Acs.Jmedchem.5B01571 |
0.634 |
|
| 2016 |
Grande F, Aiello F, Garofalo A, Neamati N. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity. Mini Reviews in Medicinal Chemistry. 16: 644-50. PMID 26955877 |
0.346 |
|
| 2015 |
Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer PM, Neamati N. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. Journal of Chemical Information and Modeling. 55: 1720-38. PMID 26153616 DOI: 10.1021/Acs.Jcim.5B00181 |
0.762 |
|
| 2015 |
Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati N. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer. 113: 242-51. PMID 26103574 DOI: 10.1038/Bjc.2015.228 |
0.513 |
|
| 2015 |
Pathania D, Kuang Y, Sechi M, Neamati N. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. British Journal of Pharmacology. 172: 50-63. PMID 25047070 DOI: 10.1111/Bph.12855 |
0.632 |
|
| 2014 |
Kumar BV, Lakshmi N, Kumar MR, Rambabu G, Manjashetty TH, Arunasree KM, Sriram D, Ramkumar K, Neamati N, Dayam R, Sarma JA. Design, synthesis and screening studies of potent thiazol-2-amine derivatives as fibroblast growth factor receptor 1 inhibitors. Current Topics in Medicinal Chemistry. 14: 2031-41. PMID 25322771 DOI: 10.2174/1568026614666141017114312 |
0.406 |
|
| 2014 |
Singh SS, Sarma JA, Narasu L, Dayam R, Xu S, Neamati N. A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors. Current Topics in Medicinal Chemistry. 14: 2020-30. PMID 25262797 DOI: 10.2174/1568026614666140929152123 |
0.574 |
|
| 2014 |
Zhang D, Debnath B, Yu S, Sanchez TW, Christ F, Liu Y, Debyser Z, Neamati N, Zhao G. Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. Bioorganic & Medicinal Chemistry. 22: 5446-53. PMID 25150089 DOI: 10.1016/J.Bmc.2014.07.036 |
0.717 |
|
| 2014 |
Ha H, Neamati N. Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. Molecular Pharmaceutics. 11: 2431-41. PMID 24896229 DOI: 10.1021/Mp500180E |
0.772 |
|
| 2014 |
Li BW, Zhang FH, Serrao E, Chen H, Sanchez TW, Yang LM, Neamati N, Zheng YT, Wang H, Long YQ. Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. Bioorganic & Medicinal Chemistry. 22: 3146-58. PMID 24794743 DOI: 10.1016/J.Bmc.2014.04.016 |
0.829 |
|
| 2014 |
Rogolino D, Carcelli M, Compari C, De Luca L, Ferro S, Fisicaro E, Rispoli G, Neamati N, Debyser Z, Christ F, Chimirri A. Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. European Journal of Medicinal Chemistry. 78: 425-30. PMID 24704615 DOI: 10.1016/J.Ejmech.2014.03.070 |
0.396 |
|
| 2014 |
Jali BR, Kuang Y, Neamati N, Baruah JB. Selective binding of naphthoquinone derivatives to serum albumin proteins and their effects on cytotoxicity. Chemico-Biological Interactions. 214: 10-7. PMID 24560625 DOI: 10.1016/J.Cbi.2014.01.014 |
0.321 |
|
| 2014 |
Serrao E, Wang CH, Frederick T, Lee CL, Anthony P, Arribas-Layton D, Baker K, Millstein J, Kovacs A, Neamati N. Alteration of select gene expression patterns in individuals infected with HIV-1. Journal of Medical Virology. 86: 678-86. PMID 24482297 DOI: 10.1002/Jmv.23872 |
0.683 |
|
| 2014 |
Ha H, Bensman T, Ho H, Beringer PM, Neamati N. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. British Journal of Pharmacology. 171: 1551-65. PMID 24354854 DOI: 10.1111/Bph.12547 |
0.765 |
|
| 2014 |
Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today. 19: 222-40. PMID 24184531 DOI: 10.1016/J.Drudis.2013.10.017 |
0.615 |
|
| 2014 |
Pathania D, Sechi M, Palomba M, Sanna V, Berrettini F, Sias A, Taheri L, Neamati N. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer. Biochimica Et Biophysica Acta. 1840: 332-43. PMID 23954204 DOI: 10.1016/J.Bbagen.2013.08.005 |
0.596 |
|
| 2013 |
Millard M, Gallagher JD, Olenyuk BZ, Neamati N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. Journal of Medicinal Chemistry. 56: 9170-9. PMID 24147900 DOI: 10.1021/Jm4012438 |
0.607 |
|
| 2013 |
Kim K, Kim JM, Kim JS, Choi J, Lee YS, Neamati N, Song JS, Heo K, An W. VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Molecular Cell. 52: 459-67. PMID 24140421 DOI: 10.1016/J.Molcel.2013.09.017 |
0.319 |
|
| 2013 |
Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion On Therapeutic Targets. 17: 1303-28. PMID 24099136 DOI: 10.1517/14728222.2013.830105 |
0.499 |
|
| 2013 |
Sangthong S, Ha H, Teerawattananon T, Ngamrojanavanich N, Neamati N, Muangsin N. Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives. Bioorganic & Medicinal Chemistry Letters. 23: 6156-60. PMID 24095089 DOI: 10.1016/J.Bmcl.2013.09.004 |
0.761 |
|
| 2013 |
Sharma H, Sanchez TW, Neamati N, Detorio M, Schinazi RF, Cheng X, Buolamwini JK. Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 6146-51. PMID 24091080 DOI: 10.1016/J.Bmcl.2013.09.009 |
0.726 |
|
| 2013 |
Yu S, Sanchez TW, Liu Y, Yin Y, Neamati N, Zhao G. Design and synthesis of novel pyrimidone analogues as HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 6134-7. PMID 24084160 DOI: 10.1016/J.Bmcl.2013.09.018 |
0.727 |
|
| 2013 |
Serrao E, Xu ZL, Debnath B, Christ F, Debyser Z, Long YQ, Neamati N. Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction. Bioorganic & Medicinal Chemistry. 21: 5963-72. PMID 23985689 DOI: 10.1016/J.Bmc.2013.07.047 |
0.765 |
|
| 2013 |
Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. Plos One. 8: e69484. PMID 23936028 DOI: 10.1371/Journal.Pone.0069484 |
0.523 |
|
| 2013 |
Saha S, Reddy ChV, Xu S, Sankar S, Neamati N, Patro B. Synthesis and SAR studies of marine natural products ma'edamines A, B and their analogues. Bioorganic & Medicinal Chemistry Letters. 23: 5135-9. PMID 23927972 DOI: 10.1016/J.Bmcl.2013.07.017 |
0.564 |
|
| 2013 |
Ji Y, Majumder S, Millard M, Borra R, Bi T, Elnagar AY, Neamati N, Shekhtman A, Camarero JA. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. Journal of the American Chemical Society. 135: 11623-33. PMID 23848581 DOI: 10.1021/Ja405108P |
0.599 |
|
| 2013 |
Long YQ, Huang SX, Zawahir Z, Xu ZL, Li H, Sanchez TW, Zhi Y, De Houwer S, Christ F, Debyser Z, Neamati N. Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 56: 5601-12. PMID 23758584 DOI: 10.1021/Jm4006516 |
0.811 |
|
| 2013 |
Xu S, Grande F, Garofalo A, Neamati N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 12: 937-49. PMID 23536726 DOI: 10.1158/1535-7163.Mct-12-1082 |
0.612 |
|
| 2013 |
Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A, Neamati N. Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Letters. 335: 421-30. PMID 23481022 DOI: 10.1016/J.Canlet.2013.02.055 |
0.539 |
|
| 2013 |
Serrao E, Debnath B, Otake H, Kuang Y, Christ F, Debyser Z, Neamati N. Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. Journal of Medicinal Chemistry. 56: 2311-22. PMID 23445471 DOI: 10.1021/Jm301632E |
0.73 |
|
| 2013 |
Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 3: 47-75. PMID 23382786 DOI: 10.7150/Thno.5376 |
0.661 |
|
| 2013 |
Shabaik YH, Millard M, Neamati N. Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. Plos One. 8: e54346. PMID 23349858 DOI: 10.1371/Journal.Pone.0054346 |
0.798 |
|
| 2013 |
Sanchez TW, Debnath B, Christ F, Otake H, Debyser Z, Neamati N. Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions. Bioorganic & Medicinal Chemistry. 21: 957-63. PMID 23306052 DOI: 10.1016/J.Bmc.2012.12.012 |
0.689 |
|
| 2013 |
Carcelli M, Bacchi A, Pelagatti P, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Neamati N. Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors. Journal of Inorganic Biochemistry. 118: 74-82. PMID 23123342 DOI: 10.1016/J.Jinorgbio.2012.09.021 |
0.689 |
|
| 2013 |
Ramkumar K, Debnath B, Lee AS, Neamati N. Abstract 5678: Design of GRP78 inhibitors as novel therapeutics for breast cancer. Cancer Research. 73: 5678-5678. DOI: 10.1158/1538-7445.Am2013-5678 |
0.44 |
|
| 2013 |
Pathania D, Sechi M, Palomba M, Sanna V, Berrettini F, Sias A, Taheri L, Neamati N. Abstract 4555: Design and discovery of novel small molecule redox modulators as therapies for pancreatic cancer. Cancer Research. 73: 4555-4555. DOI: 10.1158/1538-7445.Am2013-4555 |
0.644 |
|
| 2012 |
Aboye TL, Ha H, Majumder S, Christ F, Debyser Z, Shekhtman A, Neamati N, Camarero JA. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. Journal of Medicinal Chemistry. 55: 10729-34. PMID 23151033 DOI: 10.1021/Jm301468K |
0.809 |
|
| 2012 |
Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. Journal of Medicinal Chemistry. 55: 9492-509. PMID 23098137 DOI: 10.1021/Jm300667V |
0.781 |
|
| 2012 |
Serrao E, Thys W, Demeulemeester J, Al-Mawsawi LQ, Christ F, Debyser Z, Neamati N. A symmetric region of the HIV-1 integrase dimerization interface is essential for viral replication. Plos One. 7: e45177. PMID 23028829 DOI: 10.1371/Journal.Pone.0045177 |
0.824 |
|
| 2012 |
Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences of the United States of America. 109: 16348-53. PMID 22988091 DOI: 10.1073/Pnas.1205226109 |
0.638 |
|
| 2012 |
Esqueda A, Mohammed MZ, Madhusudan S, Neamati N. Purification and specific assays for measuring APE-1 endonuclease activity. Methods in Molecular Biology (Clifton, N.J.). 928: 161-74. PMID 22956141 DOI: 10.1007/978-1-62703-008-3_13 |
0.373 |
|
| 2012 |
Aiello F, Shabaik Y, Esqueda A, Sanchez TW, Grande F, Garofalo A, Neamati N. Design and synthesis of 3-carbamoylbenzoic acid derivatives as inhibitors of human apurinic/apyrimidinic endonuclease 1 (APE1). Chemmedchem. 7: 1825-39. PMID 22952012 DOI: 10.1002/Cmdc.201200334 |
0.825 |
|
| 2012 |
Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. Journal of Medicinal Chemistry. 55: 6645-68. PMID 22650325 DOI: 10.1021/Jm300207S |
0.568 |
|
| 2012 |
Yu S, Zhang L, Yan S, Wang P, Sanchez T, Christ F, Debyser Z, Neamati N, Zhao G. Nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity. Journal of Enzyme Inhibition and Medicinal Chemistry. 27: 628-40. PMID 22233539 DOI: 10.3109/14756366.2011.604851 |
0.728 |
|
| 2012 |
Yadav MR, Grande F, Chouhan BS, Naik PP, Giridhar R, Garofalo A, Neamati N. Cytotoxic potential of novel 6,7-dimethoxyquinazolines. European Journal of Medicinal Chemistry. 48: 231-43. PMID 22209417 DOI: 10.1016/J.Ejmech.2011.12.020 |
0.381 |
|
| 2012 |
Cao B, Wang Y, Ding K, Neamati N, Long YQ. Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen-Schmidt condensation, displaying diverse biological activities as curcumin analogues. Organic & Biomolecular Chemistry. 10: 1239-45. PMID 22179573 DOI: 10.1039/C1Ob06773G |
0.397 |
|
| 2012 |
Al-Safi RI, Odde S, Shabaik Y, Neamati N. Small-molecule inhibitors of APE1 DNA repair function: an overview. Current Molecular Pharmacology. 5: 14-35. PMID 22122462 DOI: 10.2174/1874467211205010014 |
0.825 |
|
| 2012 |
Xu S, Oshima T, Grande F, Neamati N, Garofalo A. Abstract 1927: Mechanistic characterization of SC144 in colon cancer Cancer Research. 72: 1927-1927. DOI: 10.1158/1538-7445.Am2012-1927 |
0.57 |
|
| 2012 |
Sutch BT, Romero RM, Neamati N, Haworth IS. Integrated teaching of structure-based drug design and biopharmaceutics: A computer-based approach Journal of Chemical Education. 89: 45-51. DOI: 10.1021/Ed200151B |
0.325 |
|
| 2012 |
Rogolino D, Carcelli M, Sechi M, Neamati N. Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design Coordination Chemistry Reviews. 256: 3063-3086. DOI: 10.1016/J.Ccr.2012.07.006 |
0.398 |
|
| 2012 |
Tambov KV, Voevodina IV, Manaev AV, Ivanenkov YA, Neamati N, Traven VF. Structures and biological activity of cinnamoyl derivatives of coumarins and dehydroacetic acid and their boron difluoride complexes Russian Chemical Bulletin. 61: 78-90. DOI: 10.1007/S11172-012-0012-Y |
0.465 |
|
| 2011 |
Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Sinisi V, Neamati N. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. Journal of Medicinal Chemistry. 54: 8407-20. PMID 22066494 DOI: 10.1021/Jm200851G |
0.664 |
|
| 2011 |
Monserrat JP, Al-Safi RI, Tiwari KN, Quentin L, Chabot GG, Vessières A, Jaouen G, Neamati N, Hillard EA. Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cells. Bioorganic & Medicinal Chemistry Letters. 21: 6195-7. PMID 21889342 DOI: 10.1016/J.Bmcl.2011.07.078 |
0.516 |
|
| 2011 |
Fan X, Zhang FH, Al-Safi RI, Zeng LF, Shabaik Y, Debnath B, Sanchez TW, Odde S, Neamati N, Long YQ. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. Bioorganic & Medicinal Chemistry. 19: 4935-52. PMID 21778063 DOI: 10.1016/J.Bmc.2011.06.058 |
0.835 |
|
| 2011 |
Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 1: 154-88. PMID 21547158 DOI: 10.7150/Thno/V01P0154 |
0.559 |
|
| 2011 |
Yamada R, Cao X, Butkevich AN, Millard M, Odde S, Mordwinkin N, Gundla R, Zandi E, Louie SG, Petasis NA, Neamati N. Discovery and preclinical evaluation of a novel class of cytotoxic propynoic acid carbamoyl methyl amides (PACMAs). Journal of Medicinal Chemistry. 54: 2902-14. PMID 21443194 DOI: 10.1021/Jm101655D |
0.623 |
|
| 2011 |
Millard M, Pathania D, Grande F, Xu S, Neamati N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Current Pharmaceutical Design. 17: 536-59. PMID 21391905 DOI: 10.2174/138161211795222649 |
0.782 |
|
| 2011 |
Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK. Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 19: 2030-45. PMID 21371895 DOI: 10.1016/J.Bmc.2011.01.047 |
0.724 |
|
| 2011 |
Stanford SM, Krishnamurthy D, Falk MD, Messina R, Debnath B, Li S, Liu T, Kazemi R, Dahl R, He Y, Yu X, Chan AC, Zhang ZY, Barrios AM, Woods VL, ... Neamati N, et al. Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. Journal of Medicinal Chemistry. 54: 1640-54. PMID 21341673 DOI: 10.1021/Jm101202J |
0.448 |
|
| 2011 |
Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Neamati N. HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding. Molecular Pharmaceutics. 8: 507-19. PMID 21323359 DOI: 10.1021/Mp100343X |
0.683 |
|
| 2011 |
Al-Mawsawi LQ, Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. Chemmedchem. 6: 228-41. PMID 21275045 DOI: 10.1002/Cmdc.201000443 |
0.799 |
|
| 2011 |
Pathania D, Sechi M, Palomba M, Cosseddu A, Sanna V, Berrettini F, Sias A, Taheri L, Neamati N. Abstract 682: Design and discovery of novel small molecule modulators of reactive oxygen species-mediated cell signaling Cancer Research. 71: 682-682. DOI: 10.1158/1538-7445.Am2011-682 |
0.628 |
|
| 2011 |
Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N. Abstract 2542: Preclinical studies of novel phosphonium salts with broad-spectrum activity Cancer Research. 71: 2542-2542. DOI: 10.1158/1538-7445.Am2011-2542 |
0.802 |
|
| 2011 |
Xu S, Grande F, Garofalo A, Neamati N. Abstract C148: SC144: The first orally active small molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C148 |
0.606 |
|
| 2011 |
Al-Mawsawi LQ, Neamati N. New Paradigm for Integrase Inhibition: Blocking Enzyme Function without Directly Targeting the Active Site Hiv-1 Integrase: Mechanism and Inhibitor Design. 457-476. DOI: 10.1002/9781118015377.ch29 |
0.711 |
|
| 2010 |
Debnath B, Al-Mawsawi LQ, Neamati N. Are we living in the end of the blockbuster drug era? Drug News & Perspectives. 23: 670-84. PMID 21180653 DOI: 10.1358/Dnp.2010.23.10.1506088 |
0.695 |
|
| 2010 |
Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N. Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. Plos One. 5. PMID 20957228 DOI: 10.1371/Journal.Pone.0013131 |
0.78 |
|
| 2010 |
Hadi V, Koh YH, Sanchez TW, Barrios D, Neamati N, Jung KW. Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold. Bioorganic & Medicinal Chemistry Letters. 20: 6854-7. PMID 20864343 DOI: 10.1016/J.Bmcl.2010.08.057 |
0.726 |
|
| 2010 |
Ramkumar K, Yarovenko VN, Nikitina AS, Zavarzin IV, Krayushkin MM, Kovalenko LV, Esqueda A, Odde S, Neamati N. Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors. Molecules (Basel, Switzerland). 15: 3958-92. PMID 20657419 DOI: 10.3390/Molecules15063958 |
0.561 |
|
| 2010 |
Ramkumar K, Serrao E, Odde S, Neamati N. HIV-1 integrase inhibitors: 2007-2008 update. Medicinal Research Reviews. 30: 890-954. PMID 20135632 DOI: 10.1002/Med.20194 |
0.753 |
|
| 2010 |
Yamada R, Kostova MB, Anchoori RK, Xu S, Neamati N, Khan SR. Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biology & Therapy. 9: 192-203. PMID 20023432 DOI: 10.4161/Cbt.9.3.10656 |
0.588 |
|
| 2010 |
Sanam R, Tajne S, Gundla R, Vadivelan S, Machiraju PK, Dayam R, Narasu L, Jagarlapudi S, Neamati N. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors. Journal of Molecular Graphics & Modelling. 28: 472-7. PMID 20005756 DOI: 10.1016/J.Jmgm.2009.11.002 |
0.437 |
|
| 2010 |
Taktakishvili M, Neamati N, Pommier Y, Nair V. ChemInform Abstract: Discovery of a Nuclease-Resistant, Non-natural Dinucleotide that Inhibits HIV-1 Integrase. Cheminform. 32: no-no. DOI: 10.1002/chin.200137210 |
0.326 |
|
| 2010 |
Priebe W, Skibicki P, Neamati N, Achmatowicz O, Grynkiewicz G, Szechner B. ChemInform Abstract: Synthesis of Kedarosamine, a Sugar Portion of the Chromoprotein Antibiotic Kedarcidine. Cheminform. 30: no-no. DOI: 10.1002/chin.199942223 |
0.414 |
|
| 2010 |
ZHAO H, NEAMATI N, POMMIER Y, BURKE TRJ. ChemInform Abstract: Design and Synthesis of Photoactivatable Coumarin-Containing HIV-1 Integrase Inhibitors. Cheminform. 29: no-no. DOI: 10.1002/chin.199816131 |
0.359 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: One-Step C-Acylation of Glycals and 2-Deoxyhexopyranoses at C-2. Cheminform. 24: no-no. DOI: 10.1002/chin.199318152 |
0.39 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N, PEREZ-SOLER R. ChemInform Abstract: A Facile Method for Preparation of 3-Thio Sugars and 3-Thio Glycals. Synthesis of 3′-Mercapto-3′-deaminodoxorubicin. Cheminform. 23: no-no. DOI: 10.1002/chin.199215301 |
0.415 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: 2-Deoxy-1-O-Silylated β-Hexopyranoses. Useful Glycosyl Donors and Synthetic Intermediates. Cheminform. 23: no-no. DOI: 10.1002/chin.199207249 |
0.398 |
|
| 2010 |
PRIEBE W, GRYNKIEWICZ G, NEAMATI N. ChemInform Abstract: Synthesis of New 1-C-(2-Furyl)- and 3-C-(2-Furyl)-hexopyranosides and 3-C-(2-Furyl)-daunorubicin Analogs. Cheminform. 22: no-no. DOI: 10.1002/chin.199135277 |
0.404 |
|
| 2009 |
Ramkumar K, Neamati N. Raltegravir: The evidence of its therapeutic value in HIV-1 infection. Core Evidence. 4: 131-47. PMID 20694070 DOI: 10.2147/Ce.S6004 |
0.461 |
|
| 2009 |
Ramajayam R, Mahera NB, Neamati N, Yadav MR, Giridhar R. Synthesis and anti-HIV-1 integrase activity of cyano pyrimidinones. Archiv Der Pharmazie. 342: 710-5. PMID 19899101 DOI: 10.1002/Ardp.200900066 |
0.454 |
|
| 2009 |
Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Advanced Drug Delivery Reviews. 61: 1250-75. PMID 19716393 DOI: 10.1016/J.Addr.2009.05.010 |
0.735 |
|
| 2009 |
Wang P, Liu C, Sanches T, Zhong Y, Liu B, Xiong J, Neamati N, Zhao G. Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester. Bioorganic & Medicinal Chemistry Letters. 19: 4574-8. PMID 19625188 DOI: 10.1016/J.Bmcl.2009.06.100 |
0.512 |
|
| 2009 |
Grande F, Yamada R, Cao X, Aiello F, Garofalo A, Neamati N. Synthesis and biological evaluation of novel hydrazide based cytotoxic agents. Expert Opinion On Investigational Drugs. 18: 555-68. PMID 19388873 DOI: 10.1517/13543780902858815 |
0.42 |
|
| 2009 |
Oshima T, Cao X, Grande F, Yamada R, Garofalo A, Louie S, Neamati N. Combination effects of SC144 and cytotoxic anticancer agents. Anti-Cancer Drugs. 20: 312-20. PMID 19322070 DOI: 10.1097/Cad.0B013E328323A7Ca |
0.385 |
|
| 2009 |
Cao X, Plasencia C, Kanzaki A, Yang A, Burke TR, Neamati N. Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Current Cancer Drug Targets. 9: 189-201. PMID 19275759 DOI: 10.2174/156800909787580971 |
0.395 |
|
| 2009 |
Li H, Wang C, Sanchez T, Tan Y, Jiang C, Neamati N, Zhao G. Amide-containing diketoacids as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity. Bioorganic & Medicinal Chemistry. 17: 2913-9. PMID 19269185 DOI: 10.1016/J.Bmc.2009.01.077 |
0.719 |
|
| 2009 |
Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology. 6: 25. PMID 19265512 DOI: 10.1186/1742-4690-6-25 |
0.744 |
|
| 2009 |
Plasencia C, Grande F, Oshima T, Cao X, Yamada R, Sanchez T, Aiello F, Garofalo A, Neamati N. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biology & Therapy. 8: 458-65. PMID 19221468 DOI: 10.4161/Cbt.8.5.7741 |
0.671 |
|
| 2009 |
Sechi M, Carta F, Sannia L, Dallocchio R, Dessì A, Al-Safi RI, Neamati N. Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes. Antiviral Research. 81: 267-76. PMID 19135482 DOI: 10.1016/J.Antiviral.2008.12.010 |
0.491 |
|
| 2009 |
Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. Journal of Medicinal Chemistry. 52: 20-32. PMID 19072053 DOI: 10.1021/Jm800739M |
0.819 |
|
| 2009 |
Sechi M, Rizzi G, Bacchi A, Carcelli M, Rogolino D, Pala N, Sanchez TW, Taheri L, Dayam R, Neamati N. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 17: 2925-35. PMID 19026554 DOI: 10.1016/J.Bmc.2008.10.088 |
0.734 |
|
| 2009 |
Brzozowski Z, Saczewski F, Sławiński J, Sanchez T, Neamati N. Synthesis and anti-HIV-1 integrase activities of 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazines. European Journal of Medicinal Chemistry. 44: 190-6. PMID 18394758 DOI: 10.1016/J.Ejmech.2008.02.004 |
0.699 |
|
| 2009 |
Serrao E, Odde S, Ramkumar K, Neamati N. Erratum to: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors Retrovirology. 6: 33. DOI: 10.1186/1742-4690-6-33 |
0.71 |
|
| 2009 |
Ramkumar K, Tambov KV, Gundla R, Manaev AV, Yarovenko V, Traven VF, Neamati N. Corrigendum to “Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors” [Bioorg. Med. Chem. 16 (2008) 8988–8998] Bioorganic & Medicinal Chemistry. 17: 929. DOI: 10.1016/J.Bmc.2008.08.082 |
0.427 |
|
| 2008 |
Deng J, Taheri L, Grande F, Aiello F, Garofalo A, Neamati N. Discovery of novel anticancer compounds based on a quinoxalinehydrazine pharmacophore. Chemmedchem. 3: 1677-86. PMID 18985651 DOI: 10.1002/Cmdc.200800217 |
0.423 |
|
| 2008 |
Bacchi A, Biemmi M, Carcelli M, Carta F, Compari C, Fisicaro E, Rogolino D, Sechi M, Sippel M, Sotriffer CA, Sanchez TW, Neamati N. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by beta-diketo acid metal complexes. Journal of Medicinal Chemistry. 51: 7253-64. PMID 18983138 DOI: 10.1021/Jm800893Q |
0.649 |
|
| 2008 |
Sechi M, Azzena U, Delussu MP, Dallocchio R, Dessì A, Cosseddu A, Pala N, Neamati N. Design and synthesis of bis-amide and hydrazide-containing derivatives of malonic acid as potential HIV-1 integrase inhibitors. Molecules (Basel, Switzerland). 13: 2442-61. PMID 18830166 DOI: 10.3390/Molecules13102442 |
0.514 |
|
| 2008 |
Ramkumar K, Tambov KV, Gundla R, Manaev AV, Manaev AV, Yarovenko V, Traven VF, Neamati N. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 16: 8988-98. PMID 18805696 DOI: 10.1016/J.Bmc.2008.08.067 |
0.543 |
|
| 2008 |
Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Novel opportunities for thymidylate metabolism as a therapeutic target. Molecular Cancer Therapeutics. 7: 3029-37. PMID 18790783 DOI: 10.1158/1535-7163.Mct-08-0280 |
0.404 |
|
| 2008 |
Zeng LF, Zhang HS, Wang YH, Sanchez T, Zheng YT, Neamati N, Long YQ. Efficient synthesis and utilization of phenyl-substituted heteroaromatic carboxylic acids as aryl diketo acid isosteres in the design of novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18: 4521-4. PMID 18662877 DOI: 10.1016/J.Bmcl.2008.07.047 |
0.702 |
|
| 2008 |
Zeng LF, Jiang XH, Sanchez T, Zhang HS, Dayam R, Neamati N, Long YQ. Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: effects of the phenyl substituent and the linker orientation. Bioorganic & Medicinal Chemistry. 16: 7777-87. PMID 18644730 DOI: 10.1016/J.Bmc.2008.07.008 |
0.708 |
|
| 2008 |
Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opinion On Emerging Drugs. 13: 213-25. PMID 18537517 DOI: 10.1517/14728214.13.2.213 |
0.776 |
|
| 2008 |
Al-Mawsawi LQ, Hombrouck A, Dayam R, Debyser Z, Neamati N. Four-tiered π interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity Virology. 377: 355-363. PMID 18514248 DOI: 10.1016/J.Virol.2008.04.030 |
0.752 |
|
| 2008 |
Gundla R, Kazemi R, Sanam R, Muttineni R, Sarma JA, Dayam R, Neamati N. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. Journal of Medicinal Chemistry. 51: 3367-77. PMID 18500794 DOI: 10.1021/Jm7013875 |
0.418 |
|
| 2008 |
Garofalo A, Grande F, Brizzi A, Aiello F, Dayam R, Neamati N. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation. Chemmedchem. 3: 986-90. PMID 18383063 DOI: 10.1002/Cmdc.200800026 |
0.521 |
|
| 2008 |
Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, Chen X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 35: 1489-98. PMID 18373091 DOI: 10.1007/S00259-008-0744-Y |
0.32 |
|
| 2008 |
Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: Insight into integrase-DNA complex formation and catalysis Febs Letters. 582: 1425-1430. PMID 18331842 DOI: 10.1016/J.Febslet.2008.02.076 |
0.72 |
|
| 2008 |
Grande F, Garofalo A, Neamati N. Small molecules anti-HIV therapeutics targeting CXCR4. Current Pharmaceutical Design. 14: 385-404. PMID 18289065 DOI: 10.2174/138161208783497714 |
0.474 |
|
| 2008 |
Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors Journal of Medicinal Chemistry. 51: 1136-1144. PMID 18281931 DOI: 10.1021/Jm070609B |
0.825 |
|
| 2008 |
Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005-2006 update. Medicinal Research Reviews. 28: 118-54. PMID 17979144 DOI: 10.1002/Med.20116 |
0.783 |
|
| 2008 |
Brzozowski Z, Sławiński J, Saczewski F, Sanchez T, Neamati N. Synthesis, anti-HIV-1 integrase, and cytotoxic activities of 4-chloro-N-(4-oxopyrimidin-2-yl)-2-mercaptobenzenesulfonamide derivatives. European Journal of Medicinal Chemistry. 43: 1188-98. PMID 17949860 DOI: 10.1016/J.Ejmech.2007.08.013 |
0.7 |
|
| 2007 |
Al-Mawsawi LQ, Dayam R, Taheri L, Witvrouw M, Debyser Z, Neamati N. Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors Bioorganic and Medicinal Chemistry Letters. 17: 6472-6475. PMID 17950601 DOI: 10.1016/J.Bmcl.2007.09.102 |
0.804 |
|
| 2007 |
Dayam R, Al-Mawsawi LQ, Neamati N. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorganic & Medicinal Chemistry Letters. 17: 6155-9. PMID 17911021 DOI: 10.1016/J.Bmcl.2007.09.061 |
0.785 |
|
| 2007 |
Al-Mawsawi LQ, Neamati N. Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. Trends in Pharmacological Sciences. 28: 526-35. PMID 17888520 DOI: 10.1016/J.Tips.2007.09.005 |
0.779 |
|
| 2007 |
Deng J, Sanchez T, Al-Mawsawi LQ, Dayam R, Yunes RA, Garofalo A, Bolger MB, Neamati N. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorganic & Medicinal Chemistry. 15: 4985-5002. PMID 17502148 DOI: 10.1016/J.Bmc.2007.04.041 |
0.834 |
|
| 2007 |
Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs in R&D. 8: 155-68. PMID 17472411 DOI: 10.2165/00126839-200708030-00003 |
0.779 |
|
| 2007 |
Al-Mawsawi LQ, Sechi M, Neamati N. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity. Febs Letters. 581: 1151-6. PMID 17328897 DOI: 10.1016/J.Febslet.2007.02.023 |
0.779 |
|
| 2007 |
Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Current Cancer Drug Targets. 7: 91-107. PMID 17305481 DOI: 10.2174/156800907780006922 |
0.431 |
|
| 2007 |
Deng J, Dayam R, Al-Mawsawi LQ, Neamati N. Design of second generation HIV-1 integrase inhibitors. Current Pharmaceutical Design. 13: 129-41. PMID 17269923 DOI: 10.2174/138161207779313687 |
0.79 |
|
| 2007 |
Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 15: 1212-28. PMID 17158051 DOI: 10.1016/J.Bmc.2006.11.026 |
0.703 |
|
| 2007 |
Grande F, Aiello F, Grazia OD, Brizzi A, Garofalo A, Neamati N. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorganic & Medicinal Chemistry. 15: 288-94. PMID 17085054 DOI: 10.1016/J.Bmc.2006.09.073 |
0.423 |
|
| 2007 |
Meadows DC, Sanchez T, Neamati N, North TW, Gervay-Hague J. Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1. Bioorganic & Medicinal Chemistry. 15: 1127-37. PMID 17074494 DOI: 10.1016/J.Bmc.2006.10.017 |
0.7 |
|
| 2007 |
Dayam R, Grande F, Al-Mawsawi LQ, Neamati N. Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu Expert Opinion On Therapeutic Patents. 17: 83-102. DOI: 10.1517/13543776.17.1.83 |
0.741 |
|
| 2006 |
Deng J, Dayam R, Neamati N. Patented small molecule inhibitors of p53-MDM2 interaction. Expert Opinion On Therapeutic Patents. 16: 165-88. PMID 20141510 DOI: 10.1517/13543776.16.2.165 |
0.426 |
|
| 2006 |
Brzozowski Z, Saczewski F, Neamati N. Synthesis and anti-HIV-1 activity of a novel series of 1,4,2-benzodithiazine-dioxides. Bioorganic & Medicinal Chemistry Letters. 16: 5298-302. PMID 16908143 DOI: 10.1002/chin.200705166 |
0.368 |
|
| 2006 |
Dayam R, Sanchez T, Neamati N. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors. Chemmedchem. 1: 238-44. PMID 16892356 DOI: 10.1002/Cmdc.200500018 |
0.737 |
|
| 2006 |
Zawahir Z, Neamati N. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. Bioorganic & Medicinal Chemistry Letters. 16: 5199-202. PMID 16879966 DOI: 10.1016/J.Bmcl.2006.07.022 |
0.812 |
|
| 2006 |
Li HY, Zawahir Z, Song LD, Long YQ, Neamati N. Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. Journal of Medicinal Chemistry. 49: 4477-86. PMID 16854053 DOI: 10.1021/Jm060307U |
0.808 |
|
| 2006 |
Sechi M, Bacchi A, Carcelli M, Compari C, Duce E, Fisicaro E, Rogolino D, Gates P, Derudas M, Al-Mawsawi LQ, Neamati N. From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. Journal of Medicinal Chemistry. 49: 4248-60. PMID 16821784 DOI: 10.1021/Jm060193M |
0.74 |
|
| 2006 |
Al-Mawsawi LQ, Fikkert V, Dayam R, Witvrouw M, Burke TR, Borchers CH, Neamati N. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proceedings of the National Academy of Sciences of the United States of America. 103: 10080-5. PMID 16785440 DOI: 10.1073/Pnas.0511254103 |
0.761 |
|
| 2006 |
Aiello F, Brizzi A, De Grazia O, Garofalo A, Grande F, Sinicropi MS, Dayam R, Neamati N. An approach to the stereo-controlled synthesis of polycyclic derivatives of l-4-thiazolidinecarboxylic acid active against HIV-1 integrase. European Journal of Medicinal Chemistry. 41: 914-7. PMID 16781021 DOI: 10.1016/J.Ejmech.2006.03.032 |
0.443 |
|
| 2006 |
Deng J, Sanchez T, Neamati N, Briggs JM. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 49: 1684-92. PMID 16509584 DOI: 10.1021/Jm0510629 |
0.686 |
|
| 2006 |
Dayam R, Deng J, Neamati N. HIV-1 integrase inhibitors: 2003-2004 update. Medicinal Research Reviews. 26: 271-309. PMID 16496343 DOI: 10.1002/Med.20054 |
0.532 |
|
| 2006 |
Deng J, Kelley JA, Barchi JJ, Sanchez T, Dayam R, Pommier Y, Neamati N. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors Bioorganic and Medicinal Chemistry. 14: 3785-3792. PMID 16460953 DOI: 10.1016/J.Bmc.2006.01.040 |
0.737 |
|
| 2006 |
Nair V, Uchil V, Neamati N. Beta-diketo acids with purine nucleobase scaffolds: novel, selective inhibitors of the strand transfer step of HIV integrase. Bioorganic & Medicinal Chemistry Letters. 16: 1920-3. PMID 16439124 DOI: 10.1016/J.Bmcl.2005.12.093 |
0.506 |
|
| 2006 |
Nair V, Chi G, Ptak R, Neamati N. HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. Journal of Medicinal Chemistry. 49: 445-7. PMID 16420027 DOI: 10.1021/Jm0508890 |
0.477 |
|
| 2006 |
Brzozowski Z, Saczewski F, Neamati N. Synthesis, antitumor and anti-HIV activities of benzodithiazine-dioxides. Bioorganic & Medicinal Chemistry. 14: 2985-93. PMID 16406643 DOI: 10.1016/J.Bmc.2005.12.024 |
0.456 |
|
| 2006 |
Dayam R, Neamati N. HIV Therapeutics, Biochemistry of Reviews in Cell Biology and Molecular Medicine. DOI: 10.1002/3527600906.Mcb.200400128 |
0.448 |
|
| 2005 |
Dayam R, Sanchez T, Neamati N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry. 48: 8009-15. PMID 16335925 DOI: 10.1021/Jm050837A |
0.723 |
|
| 2005 |
Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Molecular Cancer Therapeutics. 4: 1105-13. PMID 16020668 DOI: 10.1158/1535-7163.Mct-04-0288 |
0.375 |
|
| 2005 |
Meadows DC, Mathews TB, North TW, Hadd MJ, Kuo CL, Neamati N, Gervay-Hague J. Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 48: 4526-34. PMID 15999991 DOI: 10.1021/Jm049171V |
0.525 |
|
| 2005 |
Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology. 339: 213-25. PMID 15996703 DOI: 10.1016/J.Virol.2005.06.008 |
0.509 |
|
| 2005 |
Deng J, Lee KW, Sanchez T, Cui M, Neamati N, Briggs JM. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 48: 1496-505. PMID 15743192 DOI: 10.1021/Jm049410E |
0.69 |
|
| 2005 |
Sechi M, Sannia L, Carta F, Palomba M, Dallocchio R, Dessì A, Derudas M, Zawahir Z, Neamati N. Design of novel bioisosteres of beta-diketo acid inhibitors of HIV-1 integrase. Antiviral Chemistry & Chemotherapy. 16: 41-61. PMID 15739621 DOI: 10.1177/095632020501600105 |
0.837 |
|
| 2005 |
Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 48: 111-20. PMID 15634005 DOI: 10.1021/Jm0496077 |
0.728 |
|
| 2004 |
Dayam R, Neamati N. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design. Bioorganic & Medicinal Chemistry. 12: 6371-81. PMID 15556755 DOI: 10.1016/J.Bmc.2004.09.035 |
0.412 |
|
| 2004 |
Sechi M, Derudas M, Dallocchio R, Dessì A, Bacchi A, Sannia L, Carta F, Palomba M, Ragab O, Chan C, Shoemaker R, Sei S, Dayam R, Neamati N. Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 47: 5298-310. PMID 15456274 DOI: 10.1021/Jm049944F |
0.423 |
|
| 2004 |
Chi G, Neamati N, Nair V. Inhibition of the strand transfer step of HIV-1 integrase by non-natural dinucleotides. Bioorganic & Medicinal Chemistry Letters. 14: 4815-7. PMID 15341930 DOI: 10.1016/J.Bmcl.2004.07.050 |
0.475 |
|
| 2004 |
Aiello F, Brizzi A, Garofalo A, Grande F, Ragno G, Dayam R, Neamati N. Synthesis of novel thiazolothiazepine based HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 12: 4459-66. PMID 15265496 DOI: 10.1016/J.Bmc.2004.05.037 |
0.496 |
|
| 2004 |
Brzozowski Z, Saczewski F, Sanchez T, Kuo CL, Gdaniec M, Neamati N. Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines. Bioorganic & Medicinal Chemistry. 12: 3663-72. PMID 15186851 DOI: 10.1016/J.Bmc.2004.04.024 |
0.743 |
|
| 2004 |
Sechi M, Angotzi G, Dallocchio R, Dessì A, Carta F, Sannia L, Mariani A, Fiori S, Sanchez T, Movsessian L, Plasencia C, Neamati N. Design and synthesis of novel dihydroxyindole-2-carboxylic acids as HIV-1 integrase inhibitors. Antiviral Chemistry & Chemotherapy. 15: 67-81. PMID 15185725 DOI: 10.1177/095632020401500203 |
0.732 |
|
| 2004 |
Long YQ, Jiang XH, Dayam R, Sanchez T, Shoemaker R, Sei S, Neamati N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. Journal of Medicinal Chemistry. 47: 2561-73. PMID 15115398 DOI: 10.1021/Jm030559K |
0.722 |
|
| 2004 |
Makhija MT, Kasliwal RT, Kulkarni VM, Neamati N. De novo design and synthesis of HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 12: 2317-33. PMID 15080929 DOI: 10.1016/J.Bmc.2004.02.005 |
0.521 |
|
| 2004 |
Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 47: 385-99. PMID 14711310 DOI: 10.1021/Jm030378I |
0.507 |
|
| 2003 |
Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Current Pharmaceutical Design. 9: 1789-802. PMID 12871197 DOI: 10.2174/1381612033454469 |
0.525 |
|
| 2003 |
Neamati N. Dipyrimidine-based inhibitors of HIV-1 integrase. Expert Opinion On Investigational Drugs. 12: 289-92. PMID 12556222 DOI: 10.1517/13543784.12.2.289 |
0.461 |
|
| 2003 |
Sechi M, Sannia L, Orecchioni M, Carta F, Paglietti G, Neamati N. Structural investigation of 3,5-disubstituted isoxazoles by 1H-nuclear magnetic resonance† Journal of Heterocyclic Chemistry. 40: 1097-1102. DOI: 10.1002/Jhet.5570400621 |
0.445 |
|
| 2002 |
Neamati N, Lin Z, Karki RG, Orr A, Cowansage K, Strumberg D, Pais GC, Voigt JH, Nicklaus MC, Winslow HE, Zhao H, Turpin JA, Yi J, Skalka AM, Burke TR, et al. Metal-dependent inhibition of HIV-1 integrase. Journal of Medicinal Chemistry. 45: 5661-70. PMID 12477350 DOI: 10.1021/Jm0201417 |
0.519 |
|
| 2002 |
Chen IJ, Neamati N, MacKerell AD. Structure-based inhibitor design targeting HIV-1 integrase. Current Drug Targets. Infectious Disorders. 2: 217-34. PMID 12462126 DOI: 10.2174/1568005023342380 |
0.399 |
|
| 2002 |
Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR, De Clercq E, Witvrouw M, Neamati N, Debyser Z. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrobial Agents and Chemotherapy. 46: 3292-7. PMID 12234864 DOI: 10.1128/Aac.46.10.3292-3297.2002 |
0.441 |
|
| 2002 |
Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 45: 3184-94. PMID 12109903 DOI: 10.1021/Jm020037P |
0.404 |
|
| 2002 |
Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. The Journal of Biological Chemistry. 277: 12596-603. PMID 11805103 DOI: 10.1074/Jbc.M110758200 |
0.501 |
|
| 2002 |
Melek M, Jones JM, O'Dea MH, Pais G, Burke TR, Pommier Y, Neamati N, Gellert M. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proceedings of the National Academy of Sciences of the United States of America. 99: 134-7. PMID 11756686 DOI: 10.1073/Pnas.012610699 |
0.311 |
|
| 2002 |
Neamati N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga Expert Opinion On Therapeutic Patents. 12: 709-724. DOI: 10.1517/13543776.12.5.709 |
0.512 |
|
| 2001 |
Zhang X, Neamati N, Lee YK, Orr A, Brown RD, Whitaker N, Pommier Y, Burke TR. Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. Bioorganic & Medicinal Chemistry. 9: 1649-57. PMID 11425564 DOI: 10.1016/S0968-0896(01)00075-X |
0.344 |
|
| 2001 |
Taktakishvili M, Neamati N, Pommier Y, Nair V. Discovery of a nuclease-resistant, non-natural dinucleotide that inhibits HIV-1 integrase. Bioorganic & Medicinal Chemistry Letters. 11: 1433-5. PMID 11378371 DOI: 10.1016/S0960-894X(01)00231-1 |
0.377 |
|
| 2001 |
Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opinion On Investigational Drugs. 10: 281-96. PMID 11178341 DOI: 10.1517/13543784.10.2.281 |
0.484 |
|
| 2000 |
Chen IJ, Neamati N, Nicklaus MC, Orr A, Anderson L, Barchi JJ, Kelley JA, Pommier Y, MacKerell AD. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorganic & Medicinal Chemistry. 8: 2385-98. PMID 11058033 DOI: 10.1016/S0968-0896(00)00180-2 |
0.433 |
|
| 2000 |
Pommier Y, Marchand C, Neamati N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Research. 47: 139-48. PMID 10974366 DOI: 10.1016/S0166-3542(00)00112-1 |
0.368 |
|
| 2000 |
Taktakishvili M, Neamati N, Pommier Y, Nair V. Recognition and inhibition of HIV integrase by a novel dinucleotide. Bioorganic & Medicinal Chemistry Letters. 10: 249-51. PMID 10698446 DOI: 10.1016/S0960-894X(99)00677-0 |
0.364 |
|
| 2000 |
Taktakishvili M, Neamati N, Pommier Y, Pal S, Nair V. Recognition and Inhibition of HIV Integrase by Novel Dinucleotides Journal of the American Chemical Society. 122: 5671-5677. DOI: 10.1021/Ja992528D |
0.342 |
|
| 2000 |
Pannecouque C, Pluymers W, Fikkert V, Neamati N, Marchand C, Burke T, Pommier Y, De Clercq E, Debyser Z, Witvrouw M. 4 Viral entry as the primary target of anti-HIV activity of chicoric acid and its tetra-acetyl esters Antiviral Research. 46: A36. DOI: 10.1016/S0166-3542(00)90335-8 |
0.328 |
|
| 1999 |
Neamati N, Turpin JA, Winslow HE, Christensen JL, Williamson K, Orr A, Rice WG, Pommier Y, Garofalo A, Brizzi A, Campiani G, Fiorini I, Nacci V. Thiazolothiazepine inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry. 42: 3334-41. PMID 10464020 DOI: 10.1021/Jm990047Z |
0.396 |
|
| 1999 |
Pommier Y, Neamati N. Inhibitors of human immunodeficiency virus integrase. Advances in Virus Research. 52: 427-58. PMID 10384246 DOI: 10.1016/S0065-3527(08)60310-3 |
0.328 |
|
| 1999 |
Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C, Strebel K, Kohn K, Witvrouw M, Pannecouque C, Debyser Z, De Clercq E, Rice WG, Pommier Y, Burke TR. Chicoric acid analogues as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry. 42: 1401-14. PMID 10212126 DOI: 10.1021/Jm980531M |
0.377 |
|
| 1999 |
Zhang J, Neamati N, Pommier Y, Nair V. Inhibition of HIV integrase by novel nucleotides bearing tricyclic bases. Bioorganic & Medicinal Chemistry Letters. 8: 1887-90. PMID 9873453 DOI: 10.1016/S0960-894X(98)00327-8 |
0.35 |
|
| 1998 |
Hong H, Neamati N, Winslow HE, Christensen JL, Orr A, Pommier Y, Milne GW. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chemistry & Chemotherapy. 9: 461-72. PMID 9865384 DOI: 10.1177/095632029800900602 |
0.461 |
|
| 1998 |
Neamati N, Hong H, Owen JM, Sunder S, Winslow HE, Christensen JL, Zhao H, Burke TR, Milne GW, Pommier Y. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. Journal of Medicinal Chemistry. 41: 3202-9. PMID 9703465 DOI: 10.1021/Jm9801760 |
0.419 |
|
| 1998 |
Neamati N, Mazumder A, Sunder S, Owen JM, Tandon M, Lown JW, Pommier Y. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase Molecular Pharmacology. 54: 280-290. PMID 9687569 DOI: 10.1124/Mol.54.2.280 |
0.373 |
|
| 1998 |
Lubkowski J, Yang F, Alexandratos J, Wlodawer A, Zhao H, Burke TR, Neamati N, Pommier Y, Merkel G, Skalka AM. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proceedings of the National Academy of Sciences of the United States of America. 95: 4831-6. PMID 9560188 DOI: 10.1073/pnas.95.9.4831 |
0.367 |
|
| 1998 |
Drake RR, Neamati N, Hong H, Pilon AA, Sunthankar P, Hume SD, Milne GWA, Pommier Y. Identification of a nucleotide binding site in HIV-1 integrase Proceedings of the National Academy of Sciences of the United States of America. 95: 4170-4175. PMID 9539708 DOI: 10.1073/pnas.95.8.4170 |
0.319 |
|
| 1998 |
Neamati N, Hong H, Sunder S, Milne GW, Pommier Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Molecular Pharmacology. 52: 1041-55. PMID 9415714 DOI: 10.1124/mol.52.6.1041 |
0.344 |
|
| 1997 |
Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E, Pommier Y. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. Journal of Medicinal Chemistry. 40: 3057-63. PMID 9301668 DOI: 10.1021/jm970190x |
0.372 |
|
| 1997 |
Zhao H, Neamati N, Mazumder A, Sunder S, Pommier Y, Burke TR. Arylamide inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry. 40: 1186-94. PMID 9111292 DOI: 10.1021/jm960449w |
0.34 |
|
| 1997 |
Mazumder A, Uchida H, Neamati N, Sunder S, Jaworska-Maslanka M, Wickstrom E, Zeng F, Jones RA, Mandes RF, Chenault HK, Pommier Y. Probing interactions between viral DNA and human immunodeficiency virus type 1 integrase using dinucleotides. Molecular Pharmacology. 51: 567-75. PMID 9106620 DOI: 10.1124/Mol.51.4.567 |
0.381 |
|
| 1997 |
Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. International Journal of Cancer. 71: 35-41. PMID 9096663 DOI: 10.1002/(Sici)1097-0215(19970328)71:1<35::Aid-Ijc8>3.0.Co;2-4 |
0.474 |
|
| 1997 |
Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Nicklaus MC, Milne GW, Proksa B, Pommier Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. Journal of Medicinal Chemistry. 40: 942-51. PMID 9083483 DOI: 10.1021/Jm960759E |
0.419 |
|
| 1997 |
Zhao H, Neamati N, Sunder S, Hong H, Wang S, Milne GW, Pommier Y, Burke TR. Hydrazide-containing inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry. 40: 937-41. PMID 9083482 DOI: 10.1021/Jm960755+ |
0.396 |
|
| 1997 |
Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, Burke TR, Pommier Y, Milne GW. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. Journal of Medicinal Chemistry. 40: 930-6. PMID 9083481 DOI: 10.1021/Jm960754H |
0.411 |
|
| 1997 |
Nicklaus MC, Neamati N, Hong H, Mazumder A, Sunder S, Chen J, Milne GW, Pommier Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. Journal of Medicinal Chemistry. 40: 920-9. PMID 9083480 DOI: 10.1021/jm960596u |
0.433 |
|
| 1997 |
Neamati N, Mazumder A, Zhao H, Sunder S, Burke TR, Schultz RJ, Pommier Y. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrobial Agents and Chemotherapy. 41: 385-93. PMID 9021196 |
0.396 |
|
| 1997 |
Zhao H, Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Milne GW, Pommier Y, Burke TR. Coumarin-based inhibitors of HIV integrase. Journal of Medicinal Chemistry. 40: 242-9. PMID 9003523 DOI: 10.1021/Jm960450V |
0.36 |
|
| 1997 |
Burke, Jr. T, Zhao H, Neamati N, Pommier Y. Design and Synthesis of Photoactivatable Coumarin-containing HIV-1 Integrase Inhibitors Heterocycles. 45: 2277. DOI: 10.3987/COM-97-7952 |
0.363 |
|
| 1996 |
Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry. 35: 13762-71. PMID 8901518 DOI: 10.1021/bi960541u |
0.344 |
|
| 1996 |
Mazumder A, Wang S, Neamati N, Nicklaus M, Sunder S, Chen J, Milne GW, Rice WG, Burke TR, Pommier Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. Journal of Medicinal Chemistry. 39: 2472-81. PMID 8691444 DOI: 10.1021/Jm960074E |
0.435 |
|
| 1992 |
Priebe W, Neamati N, Perez-soler R. 3'-Hydroxyesorubicin halogenated at C-2'. The Journal of Antibiotics. 45: 386-93. PMID 1577666 DOI: 10.7164/Antibiotics.45.386 |
0.514 |
|
| 1992 |
Priebe W, Grynkiewicz G, Neamati N. One step C-acylation of glycals and 2-deoxy-hexopyranoses at C-2 Tetrahedron Letters. 33: 7681-7684. DOI: 10.1016/0040-4039(93)88015-B |
0.412 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N, Perez-Soler R. A facile method for preparation of 3-thio-sugars and 3-thio-glycals. synthesis of 3′-mercapto-3′-deamino-doxorubicin Tetrahedron Letters. 32: 3313-3316. DOI: 10.1016/S0040-4039(00)92694-7 |
0.427 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N. 2-Deoxy-1-O-silylated-β-hexopyranoses. Useful glycosyl donors and synthetic intermediates. Tetrahedron Letters. 32: 2079-2082. DOI: 10.1016/S0040-4039(00)71241-X |
0.415 |
|
| 1991 |
Priebe W, Grynkiewicz G, Neamati N. Synthesis of new 1-C-(2-furyl)-and 3-C-(2-furyl)-hexopyranosides and 3-C-(2-furyl)-daunorubicin analogs Monatshefte F�R Chemie Chemical Monthly. 122: 419-423. DOI: 10.1007/Bf00809663 |
0.404 |
|
| 1990 |
Priebe W, Neamati N, Perez-Soler R. 3'-Hydroxyesorubicin. Synthesis and antitumor activity. The Journal of Antibiotics. 43: 838-46. PMID 2387778 DOI: 10.7164/Antibiotics.43.838 |
0.492 |
|
| Show low-probability matches. |
